Levosimendan Fmk (Levosimendan)

Levosimendan works by binding to troponin C in cardiac muscle, increasing its sensitivity to calcium, which boosts contractile force without raising intracellular calcium levels. Simultaneously, it opens ATP‑sensitive potassium channels in vascular smooth muscle, leading to vasodilation and reduced afterload.

The dosage of Levosimendan is determined by the prescribing clinician based on the patient’s clinical condition, weight, and response. The product is supplied as an intravenous solution, and the prescriber sets the infusion rate and duration according to approved guidelines.

The safety of Levosimendan in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Unlike traditional catecholamine inotropes, Levosimendan increases contractility without markedly raising intracellular calcium, which may reduce the risk of arrhythmias. Its combined vasodilatory effect also lowers afterload, offering a distinct therapeutic profile compared with agents such as dobutamine or milrinone.

Levosimendan Fmk should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the solution in its original packaging until use, and discard any product that has been exposed to temperatures outside the recommended range.

Levosimendan is given as an intravenous infusion. The prescriber determines the infusion rate and duration, typically starting with a loading dose followed by a maintenance infusion, all performed under continuous monitoring of cardiovascular parameters.

The most serious risks include severe hypotension, ventricular arrhythmias, myocardial ischemia, and allergic reactions such as anaphylaxis. Patients should be closely monitored for blood pressure, heart rhythm, and signs of ischemia throughout the infusion and afterward.

Levosimendan is contraindicated in patients with known hypersensitivity to the drug, severe hypotension, or uncontrolled ventricular arrhythmias. Caution is also advised in individuals with significant renal or hepatic impairment, and it should be avoided in patients receiving other potent vasodilators without careful monitoring.